Business Context and Reporting Period
This Form 8-K, dated September 26, 2018, reports that Brooks Automation, Inc. (the "Registrant") entered into a definitive Merger Agreement to acquire GENEWIZ Group. The filing was signed by Jason W. Joseph, Senior Vice President, General Counsel and Secretary. The Registrant is incorporated in Delaware and is not an emerging growth company.
Key Financial Metrics and Transaction Details
- Transaction Type: Reverse triangular merger.
- Aggregate Cash Purchase Price: $450.0 million, subject to adjustments for cash, transaction expenses, net working capital, indebtedness, and accounts receivable.
- Funding Sources: Cash on hand and borrowings.
- Debt Facility: A commitment for a $350.0 million senior secured incremental term loan facility under an existing Credit Agreement dated October 4, 2017.
- Equity Treatment: All outstanding GENEWIZ shares and "in-the-money" stock options will be cancelled and converted into rights to receive Merger Consideration. Out-of-the-money options will be cancelled.
Material Changes and Transaction Structure
The primary material change is the entry into the Merger Agreement. The transaction structure involves a merger between Darwin Acquisition Company (a wholly-owned subsidiary of Brooks) and GENEWIZ, with GENEWIZ surviving as a wholly-owned subsidiary of Brooks. The agreement includes customary representations, warranties, covenants, and post-closing indemnification provisions. The closing is expected in the fourth quarter of 2018, subject to customary conditions including antitrust clearance under the Hart-Scott-Rodino Act.
Outlook, Risks, and Contingencies
- Closing Timeline: Expected in Q4 2018; the agreement may be terminated if closing does not occur prior to March 31, 2019.
- Regulatory Risk: Closing is contingent upon antitrust clearance.
- Financial Contingencies: The final purchase price is subject to adjustment based on GENEWIZ's financial metrics at closing.
- Management Commentary: The Board of Directors of both Brooks and GENEWIZ, as well as the requisite stockholders of GENEWIZ, have approved the agreement.
Investor Verification Checklist
- Verify the final adjusted Merger Consideration amount post-closing adjustments.
- Confirm the successful receipt of antitrust clearance under the Hart-Scott-Rodino Act.
- Review the terms of the $350.0 million senior secured incremental term loan facility and its impact on Brooks' leverage ratios.
- Monitor the closing date to ensure it occurs before the March 31, 2019 termination deadline.
- Examine the full Merger Agreement when filed in the Form 10-K for the fiscal year ending September 30, 2018, for detailed indemnification and termination clauses.